16:24 EDT Evolus (EOLS) sees FY25 revenue $295M-$305M, consensus $348.2M
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EOLS:
- Evolus, Inc. Advances NUCEIVA Safety Study: Key Insights for Investors
- Evolus launches Nuceiva neurotoxin in France through Symatese partnership
- Evolus: Strategic Positioning and Growth Potential Drive Buy Rating
- Closing Bell Movers: Gitlab down 13%, Dave & Busters up 10% post earnings
- Evolus director buys $189K in common stock